The US Food and Drug Administration (FDA) on Tuesday released a warning letter sent to Orange, CA-based distributor NuCare Pharmaceuticals after the company failed to correct certain drug listings.
The Food and Drug Administration is meeting next month to consider easing restrictions on several peptides, a group of ...
The new roster of the FDA’s advisory panel on drug compounding contains several members who would benefit from the agency ...
Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical ...
On April 30, 2026, the U.S. Food and Drug Administration (FDA) announced a proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulk Drug Substances List (“503B Bulks ...
An FDA hearing in late July may lead to a peptides boom. What consumers and investors need to know.
The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. The agency’s move means that compounding pharmacies will have to halt ...
Compounded versions of GLP-1 drugs are not approved by the FDA, and serious concerns with these drugs have been identified, including dosing errors, unapproved salt forms, and adverse events that have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results